Independent fund research. Built on SEC filings.

How we research funds

ETF · International Stock · DWS (Xtrackers)

Novo Nordisk A/S (B Shares) ADRhedged (NVOH)

Ticker NVOH · · Holdings as of Jun 30, 2026

Expense ratio
0.19%$19/yr per $10k
Net assets
$4.2Mall share classes
Holdings
3

Bottom line

Is NVOH a good fund? The bottom line

NVOH is a managed international stock ETF from DWS (Xtrackers).

Annual fees run 0.19% — about $19 a year on every $10,000 invested, cheaper than 94% of international stock funds we track.

With $4.2 million in net assets and 3 holdings, its largest position is Novo Nordisk A/s (96.9%) and the top 10 make up 99.6% of the portfolio.

What stands out

  • Low cost: cheaper than 94% of international stock peers

What to watch

  • Concentrated: top 10 holdings are 99.6% of assets
  • Small fund ($4.2 million) — small funds are likelier to close

Updated Nov 19, 2026

What NVOH invests in

The Novo Nordisk A/S (B Shares) ADRhedged (the Series) seeks to provide investment results that correspond generally, before fees and expenses, to the total return of the ordinary shares of Novo Nordisk A/S (B Shares) in its local market.

The Series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (ADRs) of the Novo Nordisk A/S (B Shares) (the Company). The Series will not invest directly in the Company. ADRs are receipts, issued by an American bank or trust issuer, which evidence ownership of underlying securities issued by a non-U.S. issuer. Generally, ADRs, issued in registered form, are designed for use in the U.S. securities markets. The Series invests in the ADRs of the Company (the Portfolio Securities) and a currency swap (the Currency Hedge Contract) designed to hedge against fluctuations in the exchange rate between the U.S. dollar and the Danish krone (Local Currency). The Currency Hedge Contract is with a counterparty acting as principal. The notional value of the Currency Hedge Contract is adjusted daily based on the current value of the Portfolio…

From the fund's prospectus (filed Apr 29, 2026).

What NVOH costs

On a $10,000 investment, NVOH's 0.19% expense ratio costs about $19 a year. The prospectus estimates $243 in total costs over 10 years (assuming 5% annual returns). The median international stock fund charges 0.9%.

See the full NVOH fee table →

NVOH top 10 holdings

#Holding% of fund
1Novo Nordisk A/s NVO96.87%
2Dreyfus Trsry Securities2.79%
3Canadian Imperial Bank Of Commerce-0.08%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 99.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to NVOH

More funds like NVOH →

NVOH FAQ

What is the expense ratio of NVOH?
NVOH's expense ratio is 0.19%, which works out to about $19 a year for every $10,000 invested. The prospectus estimates total costs of $243 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is NVOH a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 94% of international stock peers; concentrated: top 10 holdings are 99.6% of assets; small fund ($4.2 million) — small funds are likelier to close. This is general information, not personalized advice.
What does NVOH hold?
NVOH's largest holdings are Novo Nordisk A/s (96.9%), Dreyfus Trsry Securities (2.8%), Canadian Imperial Bank Of Commerce (-0.1%). It holds 3 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages NVOH?
NVOH is offered by DWS (Xtrackers) through Precidian ETFs Trust.